Dr. Clay Siegall is a distinguished and well-respected professional in his field of biotechnology. He received a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland. He currently serves as the President, the Chief Executive Officer and the Chairman on the Board of Seattle Genetics, Inc. He co-founded the company in 1998 to help focus on the unmet medical needs in oncology. The biotechnology company develops and commercializes antibody-based therapies for the treatment of cancer.
He spearheaded Seattle Genetics capital-raising programs securing more than $1.2 billion which includes the company’s initial public offering. These monies have helped develop antibody-based cancer therapies such as ADCETRIS which was approved by the U.S. Food and Drug Administration in 2011 and is available in 65 countries. Furthermore, the product is under clinical development for expansion into treatment for CD30-expressing lymphomas. ADCETRIS was developed in collaboration with Takeda Pharmaceutical Company Limited. Seattle Genetics continues to collaborate with other biotechnology and pharmaceutical companies in oncology in order to address the needs of cancer patients.
Dr. Siegall brings a wealth of knowledge to his position due to his broad pharmaceutical industry experience. He worked for the National Cancer Institute from 1988 to 1991 and for the Bristol-Myers Squibb Pharmaceutical Research Institute for the following six years before establishing Seattle Genetics.
He also serves on the Board of Directors of Ultragenx Pharmaceutical, Alder Biopharmaceuticals, Washington Roundtable and Mirna Therapeutics. The latter is a biotechnology company focused on the development and commercialization of microRNA to help combat cancer tumors.
Dr. Siegall has received numerous accolades, including the University of Maryland Alumnus of the Year for Computer, Math and Sciences in 2013 and the Northwest Ernst & Young Entrepreneur of the Year in 2012. In addition, he holds 15 patents and has authored more than 70 publications.